Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes

Ibrahim Aldoss; Raju Pillai; Dongyun Yang; Lixin Yang; Shukaib Arslan; Sally Mokhtari; Monzr M.Al Malki; Amandeep Salhotra; Shilpa Shahani; Haris Ali; Matthew Mei; Andrew Artz; David Snyder; Michelle Afkhami; Saro Armenian; Anthony Stein; Guido Marcucci; Stephen J. Forman; Ryotaro Nakamura; Vinod Pullarkat

doi:10.1038/s41408-021-00516-1

Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes

Ibrahim Aldoss
, Raju Pillai
, Dongyun Yang
, Lixin Yang
, Shukaib Arslan
, Sally Mokhtari
, Monzr M.Al Malki
, Amandeep Salhotra
, Shilpa Shahani
, Haris Ali
, Matthew Mei
, Andrew Artz
, David Snyder
, Michelle Afkhami
, Saro Armenian
, Anthony Stein
, Guido Marcucci
, Stephen J. Forman
, Ryotaro Nakamura
, Vinod Pullarkat

Center for Clinical and Translational Science

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English
Article number	125
Journal	Blood Cancer Journal
Volume	11
Issue number	7
DOIs	https://doi.org/10.1038/s41408-021-00516-1
State	Published - Jul 2021

Access to Document

10.1038/s41408-021-00516-1

Cite this

Aldoss, I., Pillai, R., Yang, D., Yang, L., Arslan, S., Mokhtari, S., Malki, M. M. A., Salhotra, A., Shahani, S., Ali, H., Mei, M., Artz, A., Snyder, D., Afkhami, M., Armenian, S., Stein, A., Marcucci, G., Forman, S. J., Nakamura, R., & Pullarkat, V. (2021). Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. Blood Cancer Journal, 11(7), Article 125. https://doi.org/10.1038/s41408-021-00516-1

@article{1cf54fbd6bf443949153944a1c3814a5,

title = "Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes",

author = "Ibrahim Aldoss and Raju Pillai and Dongyun Yang and Lixin Yang and Shukaib Arslan and Sally Mokhtari and Malki, \{Monzr M.Al\} and Amandeep Salhotra and Shilpa Shahani and Haris Ali and Matthew Mei and Andrew Artz and David Snyder and Michelle Afkhami and Saro Armenian and Anthony Stein and Guido Marcucci and Forman, \{Stephen J.\} and Ryotaro Nakamura and Vinod Pullarkat",

note = "Funding Information: This study was partially funded by the NIH, P30 CA033572 grant (Biostatistics Core). Funding Information: I.A. serves on an advisory board with Amgen, KiTE, Abbvie and Agios, he is a consultant for Autolus Therapeutics, and he received research support from MacroGenics and Abbvie. A.S. has served as consultant for Kadmon Corporation and research funding from Celgene. R.N. serves on advisory boards with Merck and Celgene and has a research collaboration with Jazz Pharmaceuticals. A.S. is on the speakers{\textquoteright} bureau for Amgen, Celgene, and Stemline. G.M. is on the speakers{\textquoteright} bureau for Abbvie. V.P. has served on the advisory boards for Abbvie and Jazz Pharmaceuticals and is member of speakers{\textquoteright} bureau for Jazz Pharmaceuticals, Amgen, Novartis, and Abbvie. The remaining authors have no relevant conflicts of interest to declare.",

year = "2021",

month = jul,

doi = "10.1038/s41408-021-00516-1",

language = "English",

volume = "11",

journal = "Blood Cancer Journal",

issn = "2044-5385",

number = "7",

}

Aldoss, I, Pillai, R, Yang, D, Yang, L, Arslan, S, Mokhtari, S, Malki, MMA, Salhotra, A, Shahani, S, Ali, H, Mei, M, Artz, A, Snyder, D, Afkhami, M, Armenian, S, Stein, A, Marcucci, G, Forman, SJ, Nakamura, R & Pullarkat, V 2021, 'Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes', Blood Cancer Journal, vol. 11, no. 7, 125. https://doi.org/10.1038/s41408-021-00516-1

TY - JOUR

T1 - Late and very late relapsed acute lymphoblastic leukemia

T2 - clinical and molecular features, and treatment outcomes

AU - Aldoss, Ibrahim

AU - Pillai, Raju

AU - Yang, Dongyun

AU - Yang, Lixin

AU - Arslan, Shukaib

AU - Mokhtari, Sally

AU - Malki, Monzr M.Al

AU - Salhotra, Amandeep

AU - Shahani, Shilpa

AU - Ali, Haris

AU - Mei, Matthew

AU - Artz, Andrew

AU - Snyder, David

AU - Afkhami, Michelle

AU - Armenian, Saro

AU - Stein, Anthony

AU - Marcucci, Guido

AU - Forman, Stephen J.

AU - Nakamura, Ryotaro

AU - Pullarkat, Vinod

N1 - Funding Information: This study was partially funded by the NIH, P30 CA033572 grant (Biostatistics Core). Funding Information: I.A. serves on an advisory board with Amgen, KiTE, Abbvie and Agios, he is a consultant for Autolus Therapeutics, and he received research support from MacroGenics and Abbvie. A.S. has served as consultant for Kadmon Corporation and research funding from Celgene. R.N. serves on advisory boards with Merck and Celgene and has a research collaboration with Jazz Pharmaceuticals. A.S. is on the speakers’ bureau for Amgen, Celgene, and Stemline. G.M. is on the speakers’ bureau for Abbvie. V.P. has served on the advisory boards for Abbvie and Jazz Pharmaceuticals and is member of speakers’ bureau for Jazz Pharmaceuticals, Amgen, Novartis, and Abbvie. The remaining authors have no relevant conflicts of interest to declare.

PY - 2021/7

Y1 - 2021/7

UR - https://www.scopus.com/pages/publications/85109016885

U2 - 10.1038/s41408-021-00516-1

DO - 10.1038/s41408-021-00516-1

M3 - Letter

C2 - 34215723

AN - SCOPUS:85109016885

SN - 2044-5385

VL - 11

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 7

M1 - 125

ER -

Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes

Access to Document

Other files and links

Cite this